Assistant Professor
-
Department of Public Health Sciences (SMD)
Credentials
Awards
Finalist, International Society for Geriatric Oncology Young Investigator Award.2023
Wilmot Doctoral Cancer Research Fellowship.2022
Dean's Fellowship Scholarship.2019
Outstanding Abstract Award.2019
Research
Dr. Mostafa Mohamed's research focuses on the intersection of cancer and aging, aiming to improve health outcomes for older adults with cancer. As a clinician and cancer epidemiologist, Dr. Mohamed brings a robust background and training in study design, causal inference, medical oncology, and geria...
Dr. Mostafa Mohamed's research focuses on the intersection of cancer and aging, aiming to improve health outcomes for older adults with cancer. As a clinician and cancer epidemiologist, Dr. Mohamed brings a robust background and training in study design, causal inference, medical oncology, and geriatric oncology research. His research interests center on two primary areas: firstly, evaluating polypharmacy and the use of high-risk medications in older adults with cancer; and secondly, exploring treatment decision-making processes, including chemotherapy dosing decisions, treatment tolerability, and efficacy of cancer therapeutics in this population. Dr Mohamed serves as a member of Junior Faculty Board of Cancer and Aging Research Group (CARG), as well as an Editorial Board member for the Journal of Geriatric Oncology.
Publications
Journal Articles
A scoping review evaluating physical and cognitive functional outcomes in cancer survivors treated with chemotherapy: charting progress since the 2018 NCI think tank on cancer and aging phenotypes
Mohamed M, Ahmed M, Williams AM, Gilmore N, Lin PJ, Yilmaz S, Jensen-Battaglia M, Mustian K, Janelsins M, Mohile S.
Journal of Cancer Survivorship. 2024; : 1-42.
Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol
Ramsdale E, Mohamed M, Holmes HM, ZubkoffL, Bauer J, Norton SA, Mohile S.
Journal of geriatric oncology. 2024; 15(2): 101687.
Primary treatment modification and treatment tolerability among older chemotherapy recipients with advanced cancer
Mohamed MR, Rich DQ, Seplaki C, Lund JL, Flannery M, Culakova E, Magnuson A, Wells M, Tylock R, Mobile SG.
AMA Network Open. 2024; 7(2): e2356106.
Modifiable fall risk factors among older adults with advanced cancer: Secondary analysis of a cluster-randomized clinical trial
Jensen-Battaglia M, Mohamed M, Loh KP, Wells M, Tylock R, Ramsdale E, Canin B, Geer J, O'Rourke MA, Liu JJ, Seplaki CL.
Journal of geriatric oncology. 2023; 14(8): 101650.
Older adults with advanced cancer report pain not captured by clinician-graded Common Terminology Criteria for Adverse Events (CTCAE)
Arana-Chicas E, Culakova E, Mohamed MR, Tylock R, Wells M, Flannery M, Mustian KM, Cupertino AP, Magnuson A, Mobile SG.
Journal of Geriatric Oncology. 2023; 14(3).
Association ofpolypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer
Mohamed MR, Mohile SG, Juba KM, Awad H, Wells M, Loh KP, Flannery M, Culakova E, Tylock RG, Ramsdale EE.
Cancer. 2023; 129(7): 1096-104.
Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer
Culakova E, Mobile SG, Peppone L, Ramsdale E, Mohamed M, Xu H, Wells M, Loh KP, Magnuson A.
Journal of Clinical Oncology. 2023; 41(4): 835-46.
External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy
Mohamed MR, Loh KP, Mobile SG, Sohn M, Webb T, Wells M, Yilmaz S, Tylock R, Culakova E, Magnuson A, Sun CL.
Journal of the National Comprehensive Cancer Network. 2023; 21(3): 273-80.
An Unsupervised Machine Leaming Approach to Evaluating the Association of Symptom Clusters With Adverse Outcomes Among Older Adults With Advanced Cancer: A Secondary Analysis of a Randomized Clinical Trial
Xu H, Mohamed M, Flannery M, Peppone L, Ramsdale E, Loh KP, Wells M, Jamieson L, Vogel VG, Hall BA, Mustian K.
JAMA network open. 2023; 6(3): e234198.
Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment.
Mohamed M, Ramsdale E, Yu V, Otto E, Juba K, Awad H, Moorthi K, Plumb S, Patil A, Vogelzang N, Dib E.
The Oncologist. 2022; 27(7): e580-8.
A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial
Presley CJ, Mohamed MR, Culakova E, Flannery M, Vibhakar PH, Hoyd R, Amini A, VanderWalde N, Wong ML, Tsubata Y, Spakowicz DJ.
Frontiers in Oncology. 2022; : 1203.
Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment
Mohamed M, Ramsdale E, Yu V, Otto E, Juba K, Awad H, Moorthi K, Plumb S, Patil A, Vogelzang N, Dib E.
The Oncologist. 2022; 27(7): e580-8.
Evaluating the association of frailty with communication about agingrelated concerns between older patients with advanced cancer and their oncologists
Gilmore N, Xu H, Kehoe L, Kleckner AS, Moorthi K, Lei L, Mohamed MR, Loh KP, Culakova E, Flannery M, Ramsdale E.
Cancer. 2022; 128(5): 1101-9.
Longitudinal changes in cognitive function in a nationwide cohort study of patients with lymphoma treated with chemotherapy
Janelsins MC, Mohamed M, Peppone LJ, Magnuson A, Belcher EK, Melnik M, Dakhil S, Geer J, Kamen C, Minasian L, Reagan PM.
JNCI: Journal of the National Cancer Institute. 2022; 114(1): 47-59.
Using geriatric assessment to guide conversations regarding comorbidities among older patients with advanced cancer
Kleckner AS, Wells M, Kehoe LA, Gilmore NJ, Xu H, Magnuson A, Dunne RF, Jensen-Battaglia M, Mohamed MR, O'Rourke MA, Vogelsong NJ.
Arastu A, Patel A, Mohile SG, Ciminelli J, Kaushik R, Wells M, Culakova E, Lei L, Xu H, Dougherty DW, Mohamed MR, Hill E, Duberstein P, Flannery MA, Kamen CS, Pandya C, Berenberg JL, Aame Grossman VG, Liu Y, Loh KP.
